{"schema_version":"secwatch.filing_event.v1","accession":"0001847367-26-000016","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2026-08-13T20:07:36+00:00","discovered_at":"2026-08-13T20:10:02.663337+00:00","generated_at":"2026-08-13T20:10:32.030664+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alumis Q2 2026: ONWARD3 shows 54% PASI 100; NDA on track for Q4","bullets":["ONWARD3: 75% PASI 90, 54% PASI 100 at 48 weeks (n=773) for envudeucitinib in PsO.","NDA submission for envudeucitinib in moderate-to-severe plaque psoriasis on track for Q4 2026.","Phase 2b LUMUS topline data in SLE expected Q3 2026; prioritizing Sjögren's and CLE.","Q2 net loss $142.2M vs net income $59.3M (incl. $187.9M ACELYRIN gain); $41.8M lonigutamab impairment.","Cash $502.3M; guidance funds into Q4 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001847367-26-000016","json":"https://secwatch.observer/filing/0001847367-26-000016.json","markdown":"https://secwatch.observer/filing/0001847367-26-000016.md","text":"https://secwatch.observer/filing/0001847367-26-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/0001847367-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:10:32.030664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}